Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 1117-1121

  Owe Larsson, Björn ^a   Ekdahl, Karin ^a   Edbom, Tobias ^a   Ösby, Urban ^b,c   Karlsson, Håkan ^b   Lundberg, Christer ^d   Lundberg, Mathias ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Karolinska Institutet ^*  (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; First episode psychosis; Oxidative stress; Schizophrenia; Thioredoxin 1

Indexed keywords

THIOREDOXIN 1;

ACUTE DISEASE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NEUROPATHOLOGY; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIOREDOXINS; YOUNG ADULT;

EID: 79956046895     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.03.012     Document Type: Article

References (22)

1. Callister M.E., Burke-Gaffney A., Quinlan G.J., Nicholson A.G., Florio R., Nakamura H., et al. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 2006, 61:521-527.
2. Dietrich-Muszalska A., Olas B., Glowacki R., Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009, 59:1-7.
3. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 2006, 32:244-252.
4. Golse B., Debray Q., Puget K., Michelson A.M. Superoxide dismutase 1 and glutathione peroxidase levels in erythrocytes of adult schizophrenics. Nouv Presse Med 1978, 7:2070-2071.
5. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 1995, 3:239-243.
6. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
7. Kwon Y.W., Masutani H., Nakamura H., Ishii Y., Yodoi J. Redox regulation of cell growth and cell death. Biol Chem 2003, 384:991-996.
8. Leaver S.K., MacCallum N.S., Pingle V., Hacking M.B., Quinlan G.J., Evans T.W., et al. Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Intensive Care Med 2010, 36:336-341.
9. Lippoldt A., Padilla C.A., Gerst H., Andbjer B., Richter E., Holmgren A., et al. Localization of thioredoxin in the rat brain and functional implications. J Neurosci 1995, 15:6747-6756.
10. Masutani H., Yodoi J. Thioredoxin. Overview. Methods Enzymol 2002, 347:279-286.
11. Miyamoto S., Kawano H., Sakamoto T., Soejima H., Kajiwara I., Hokamaki J., et al. Increased plasma levels of thioredoxin in patients with coronary spastic angina. Antioxid Redox Signal 2004, 6:75-80.
12. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
13. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1178-1183.
14. Sehlin D., Sollvander S., Paulie S., Brundin R., Ingelsson M., Lannfelt L., et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis 2010, 21:1295-1301.
15. Takahashi K., Chin K., Nakamura H., Morita S., Sumi K., Oga T., et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal 2008, 10:715-726.
16. Wahlgren C.M., Pekkari K. Elevated thioredoxin after angioplasty in peripheral arterial disease. Eur J Vasc Endovasc Surg 2005, 29:281-286.
17. Wang J.F., Shao L., Sun X., Young L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009, 11:523-529.
18. Yao J.K., Reddy R.D., van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999, 45:1512-1515.
19. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
20. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.
21. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300.
22. Zhang X.Y., Chen da C., Xiu M.H., Wang F., Qi L.Y., Sun H.Q., et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 2009, 113:151-157.